Literature DB >> 12587952

Comparison of in vitro hepatic models for the prediction of metabolic interaction between simvastatin and naringenin.

N Le Goff1, J C Koffel, S Vandenschrieck, L Jung, G Ubeaud.   

Abstract

The study of potential interaction at a very early stage of drug development requires suitable in vitro models that describe drug interactions both qualitatively and quantitatively. The purpose of this work was to help assessing the predictive value of in vitro drug interaction test with liver microsomal fractions and hepatocytes by determination of enzymatic parameters such as the inhibition constant (Ki) and the intrinsic clearance (Clint). This study was conducted to compare different methods of Ki calculation and to determine the most suitable parameter for describing drug interactions. The metabolic interaction between SV and NRG was used as a model to help verifying the suitability of the in vitro model for predicting the kind and degree of metabolic drug interactions. The method of Ki calculation using linearized versions of Michaelis Menten equations based on the simultaneous non linear regressions and the "km app" approach accurately estimated the Ki values. The linear representation of an inherently non linear relationship was only used to establish the mechanism of inhibition and the Clint could be used to predict drug interactions. To further prediction in humans, it seems likely that the simultaneous application of both systems, microsomal fractions and hepatocytes will yield conclusions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12587952     DOI: 10.1007/BF03192333

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  24 in total

1.  Grapefruit juice activates P-glycoprotein-mediated drug transport.

Authors:  A Soldner; U Christians; M Susanto; V J Wacher; J A Silverman; L Z Benet
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

2.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

3.  The determination of enzyme inhibitor constants.

Authors:  M DIXON
Journal:  Biochem J       Date:  1953-08       Impact factor: 3.857

Review 4.  Physiological disposition of HMG-CoA-reductase inhibitors.

Authors:  D E Duggan; S Vickers
Journal:  Drug Metab Rev       Date:  1990       Impact factor: 4.518

5.  Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans.

Authors:  P J Pentikainen; M Saraheimo; J I Schwartz; R D Amin; M S Schwartz; F Brunner-Ferber; J D Rogers
Journal:  J Clin Pharmacol       Date:  1992-02       Impact factor: 3.126

6.  Interaction of citrus juices with felodipine and nifedipine.

Authors:  D G Bailey; J D Spence; C Munoz; J M Arnold
Journal:  Lancet       Date:  1991-02-02       Impact factor: 79.321

7.  Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data.

Authors:  G Ubeaud; C Schmitt; D Jaeck; T Lave; P Coassolo
Journal:  Xenobiotica       Date:  1995-12       Impact factor: 1.908

8.  Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.

Authors:  J J Lilja; K T Kivistö; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  1998-11       Impact factor: 6.875

9.  Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. 4.

Authors:  B K Tang; W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  Simultaneous determination of simvastatin and its hydroxy acid form in human plasma by high-performance liquid chromatography with UV detection.

Authors:  G Carlucci; P Mazzeo; L Biordi; M Bologna
Journal:  J Pharm Biomed Anal       Date:  1992-09       Impact factor: 3.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.